{
    "xml": "<topic id=\"PHP34544\" outputclass=\"drugClass\" rev=\"1.19\" type=\"drugClass\" namespace=\"/drug-classes/aminoglycosides\" basename=\"aminoglycosides\" title=\"AMINOGLYCOSIDES\">\n<title>AMINOGLYCOSIDES</title>\n<topic id=\"PHP72865\" outputclass=\"contraindications\" rev=\"1.20\" parent=\"/drug-classes/aminoglycosides\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Myasthenia gravis (aminoglycosides may impair neuromuscular transmission)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72879\" outputclass=\"cautions\" rev=\"1.43\" parent=\"/drug-classes/aminoglycosides\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<title>General cautions:</title>\n<p>\n<ph outputclass=\"caution\">Care must be taken with dosage (the main side-effects of the aminoglycosides are dose-related)</ph>; <ph outputclass=\"caution\">conditions characterised by muscular weakness (aminoglycosides may impair neuromuscular transmission)</ph>; <ph outputclass=\"caution\">if possible, dehydration should be corrected before starting an aminoglycoside</ph>\n</p>\n<sectiondiv outputclass=\"additionalCautions\">\n<p outputclass=\"title\">Specific cautions:</p>\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\n<p outputclass=\"title\">With intramuscular use</p>\n<p>\n<ph outputclass=\"caution\">whenever possible, parenteral treatment should not exceed 7 days</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"caution\">whenever possible, parenteral treatment should not exceed 7 days</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72803\" outputclass=\"interactions\" rev=\"1.26\" parent=\"/drug-classes/aminoglycosides\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (aminoglycosides).</p>\n<p>If possible, aminoglycosides should not be given with potentially ototoxic drugs (e.g. cisplatin). Administration of an aminoglycoside and of an ototoxic diuretic (e.g. furosemide) should be separated by as long a period as practicable.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72728\" outputclass=\"sideEffects\" rev=\"1.51\" parent=\"/drug-classes/aminoglycosides\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Antibiotic-associated colitis</ph>; <ph outputclass=\"sideEffect\">electrolyte disturbances</ph>; <ph outputclass=\"sideEffect\">hypocalcaemia</ph>; <ph outputclass=\"sideEffect\">hypokalaemia</ph>; <ph outputclass=\"sideEffect\">hypomagnesaemia on prolonged therapy</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">stomatitis</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Blood disorders</ph>; <ph outputclass=\"sideEffect\">CNS effects</ph>; <ph outputclass=\"sideEffect\">convulsions</ph>; <ph outputclass=\"sideEffect\">encephalopathy</ph>; <ph outputclass=\"sideEffect\">headache</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Auditory damage</ph>; <ph outputclass=\"sideEffect\">impaired neuromuscular transmission</ph>; <ph outputclass=\"sideEffect\">impaired neuromuscular transmission</ph>; <ph outputclass=\"sideEffect\">irreversible ototoxicity</ph>; <ph outputclass=\"sideEffect\">nephrotoxicity</ph>; <ph outputclass=\"sideEffect\">transient myasthenic syndrome in patients with normal neuromuscular function with large doses given during surgery</ph>; <ph outputclass=\"sideEffect\">vestibular damage</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Nephrotoxicity</p>\n<p>Occurs most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72782\" outputclass=\"pregnancy\" parent=\"/drug-classes/aminoglycosides\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin. The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInPregnancy\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>If given during pregnancy, serum-aminoglycoside concentration monitoring is essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72762\" outputclass=\"renalImpairment\" parent=\"/drug-classes/aminoglycosides\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20&#8239;mL/ minute.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Ototoxicity and nephrotoxicity occur commonly in patients with renal failure.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Serum-aminoglycoside concentrations <b>must</b> be monitored in patients with renal impairment; earlier and more frequent measurement of aminoglycoside concentration may be required.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72710\" outputclass=\"monitoringRequirements\" parent=\"/drug-classes/aminoglycosides\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"therapeuticDrugMonitoring\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use</p>\n<p outputclass=\"title\">Serum concentrations</p>\n<p>Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy.</p>\n<p>Serum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides and <b>must </b>be determined in obesity, if high doses are being given and in cystic fibrosis.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Serum aminoglycoside concentrations <b>must</b> be determined in the elderly.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen and after a dose change.</p>\n<p>For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (&#8216;peak&#8217; concentration) and also just before the next dose (&#8216;trough&#8217; concentration). If the pre-dose (&#8216;trough&#8217;) concentration is high, the interval between doses must be increased. If the post-dose (&#8216;peak&#8217;) concentration is high, the dose must be decreased.</p>\n<p>For once daily dose regimens, consult local guidelines on serum concentration monitoring.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Renal function should be assessed before starting an aminoglycoside and during treatment.</p>\n<p>Auditory and vestibular function should also be monitored during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugClasses\" href=\"#drugClasses\" title=\"Drug classes\" namespace=\"/drug-classes\">Drug classes</xref>\n</parents>\n<drugs>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3478\" title=\"GENTAMICIN\" namespace=\"/drugs/gentamicin\">GENTAMICIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3486\" title=\"AMIKACIN\" namespace=\"/drugs/amikacin\">AMIKACIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3492\" title=\"TOBRAMYCIN\" namespace=\"/drugs/tobramycin\">TOBRAMYCIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3636\" title=\"STREPTOMYCIN\" namespace=\"/drugs/streptomycin\">STREPTOMYCIN</xref>\n</drugs>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugClasses\" href=\"#drugClasses\" namespace=\"/drug-classes\" title=\"Drug classes\" count=\"1\" rel=\"link\">Drug classes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3478\" namespace=\"/drugs/gentamicin\" title=\"GENTAMICIN\" count=\"1\" rel=\"link\">GENTAMICIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3486\" namespace=\"/drugs/amikacin\" title=\"AMIKACIN\" count=\"1\" rel=\"link\">AMIKACIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3492\" namespace=\"/drugs/tobramycin\" title=\"TOBRAMYCIN\" count=\"1\" rel=\"link\">TOBRAMYCIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP3636\" namespace=\"/drugs/streptomycin\" title=\"STREPTOMYCIN\" count=\"1\" rel=\"link\">STREPTOMYCIN</xref>\n</links>\n</topic>",
    "id": "PHP34544",
    "outputclass": "drugClass",
    "rev": "1.19",
    "type": "drugClass",
    "namespace": "/drug-classes/aminoglycosides",
    "basename": "aminoglycosides",
    "title": "AMINOGLYCOSIDES",
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Myasthenia gravis (aminoglycosides may impair neuromuscular transmission)",
                "html": "Myasthenia gravis (aminoglycosides may impair neuromuscular transmission)"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Care must be taken with dosage (the main side-effects of the aminoglycosides are dose-related)",
                "html": "Care must be taken with dosage (the main side-effects of the aminoglycosides are dose-related)"
            },
            {
                "type": "cautions",
                "textContent": "conditions characterised by muscular weakness (aminoglycosides may impair neuromuscular transmission)",
                "html": "conditions characterised by muscular weakness (aminoglycosides may impair neuromuscular transmission)"
            },
            {
                "type": "cautions",
                "textContent": "if possible, dehydration should be corrected before starting an aminoglycoside",
                "html": "if possible, dehydration should be corrected before starting an aminoglycoside"
            }
        ],
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "whenever possible, parenteral treatment should not exceed 7 days",
                "html": "whenever possible, parenteral treatment should not exceed 7 days",
                "specificity": {
                    "textContent": "With intramuscular use",
                    "html": "With intramuscular use",
                    "routes": [
                        "intramuscular"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "whenever possible, parenteral treatment should not exceed 7 days",
                "html": "whenever possible, parenteral treatment should not exceed 7 days",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (aminoglycosides).\n\nIf possible, aminoglycosides should not be given with potentially ototoxic drugs (e.g. cisplatin). Administration of an aminoglycoside and of an ototoxic diuretic (e.g. furosemide) should be separated by as long a period as practicable.",
                "html": "<p>Appendix 1 (aminoglycosides).</p><p>If possible, aminoglycosides should not be given with potentially ototoxic drugs (e.g. cisplatin). Administration of an aminoglycoside and of an ototoxic diuretic (e.g. furosemide) should be separated by as long a period as practicable.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Antibiotic-associated colitis",
                        "html": "Antibiotic-associated colitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "electrolyte disturbances",
                        "html": "electrolyte disturbances",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypocalcaemia",
                        "html": "hypocalcaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypokalaemia",
                        "html": "hypokalaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypomagnesaemia on prolonged therapy",
                        "html": "hypomagnesaemia on prolonged therapy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "stomatitis",
                        "html": "stomatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Blood disorders",
                        "html": "Blood disorders",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "CNS effects",
                        "html": "CNS effects",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "convulsions",
                        "html": "convulsions",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "encephalopathy",
                        "html": "encephalopathy",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Auditory damage",
                        "html": "Auditory damage",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "impaired neuromuscular transmission",
                        "html": "impaired neuromuscular transmission",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "impaired neuromuscular transmission",
                        "html": "impaired neuromuscular transmission",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "irreversible ototoxicity",
                        "html": "irreversible ototoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nephrotoxicity",
                        "html": "nephrotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "transient myasthenic syndrome in patients with normal neuromuscular function with large doses given during surgery",
                        "html": "transient myasthenic syndrome in patients with normal neuromuscular function with large doses given during surgery",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vestibular damage",
                        "html": "vestibular damage",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Nephrotoxicity",
                "textContent": "Occurs most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.",
                "html": "<p>Occurs most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin. The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential.",
                "html": "<p>There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin. The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "specificity": {
                    "textContent": "With intramuscular use or intravenous use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intramuscular",
                        "intravenous"
                    ]
                },
                "textContent": "If given during pregnancy, serum-aminoglycoside concentration monitoring is essential.",
                "html": "<p>If given during pregnancy, serum-aminoglycoside concentration monitoring is essential.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well.",
                "html": "<p>If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment.",
                "html": "<p>Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment.</p>"
            },
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20 mL/ minute.",
                "html": "<p>A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20&#8239;mL/ minute.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Ototoxicity and nephrotoxicity occur commonly in patients with renal failure.",
                "html": "<p>Ototoxicity and nephrotoxicity occur commonly in patients with renal failure.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "specificity": {
                    "textContent": "With intramuscular use or intravenous use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intramuscular",
                        "intravenous"
                    ]
                },
                "textContent": "Serum-aminoglycoside concentrations must be monitored in patients with renal impairment; earlier and more frequent measurement of aminoglycoside concentration may be required.",
                "html": "<p>Serum-aminoglycoside concentrations <b>must</b> be monitored in patients with renal impairment; earlier and more frequent measurement of aminoglycoside concentration may be required.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "therapeuticDrugMonitoring": [
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "With intramuscular use or intravenous use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intramuscular",
                        "intravenous"
                    ]
                },
                "title": "Serum concentrations",
                "textContent": "Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy.\n\nSerum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides and must be determined in obesity, if high doses are being given and in cystic fibrosis.",
                "html": "<p>Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy.</p><p>Serum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides and <b>must </b>be determined in obesity, if high doses are being given and in cystic fibrosis.</p>"
            },
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "With intramuscular use or intravenous use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intramuscular",
                        "intravenous"
                    ]
                },
                "textContent": "Serum aminoglycoside concentrations must be determined in the elderly.",
                "html": "<p>Serum aminoglycoside concentrations <b>must</b> be determined in the elderly.</p>"
            },
            {
                "type": "therapeuticDrugMonitoring",
                "specificity": {
                    "textContent": "With intramuscular use or intravenous use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use or <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intramuscular",
                        "intravenous"
                    ]
                },
                "textContent": "In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen and after a dose change.\n\nFor multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (&#8216;peak&#8217; concentration) and also just before the next dose (&#8216;trough&#8217; concentration). If the pre-dose (&#8216;trough&#8217;) concentration is high, the interval between doses must be increased. If the post-dose (&#8216;peak&#8217;) concentration is high, the dose must be decreased.\n\nFor once daily dose regimens, consult local guidelines on serum concentration monitoring.",
                "html": "<p>In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen and after a dose change.</p><p>For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (&#8216;peak&#8217; concentration) and also just before the next dose (&#8216;trough&#8217; concentration). If the pre-dose (&#8216;trough&#8217;) concentration is high, the interval between doses must be increased. If the post-dose (&#8216;peak&#8217;) concentration is high, the dose must be decreased.</p><p>For once daily dose regimens, consult local guidelines on serum concentration monitoring.</p>"
            }
        ],
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Renal function should be assessed before starting an aminoglycoside and during treatment.\n\nAuditory and vestibular function should also be monitored during treatment.",
                "html": "<p>Renal function should be assessed before starting an aminoglycoside and during treatment.</p><p>Auditory and vestibular function should also be monitored during treatment.</p>"
            }
        ]
    },
    "drugsInClass": [
        {
            "id": "PHP3478",
            "label": "GENTAMICIN",
            "type": "drug"
        },
        {
            "id": "PHP3486",
            "label": "AMIKACIN",
            "type": "drug"
        },
        {
            "id": "PHP3492",
            "label": "TOBRAMYCIN",
            "type": "drug"
        },
        {
            "id": "PHP3636",
            "label": "STREPTOMYCIN",
            "type": "drug"
        }
    ],
    "backlinks": {},
    "links": {
        "#drugClasses": [
            {
                "id": "drugClasses",
                "label": "Drug classes",
                "type": "#drugClasses"
            }
        ],
        "drug": [
            {
                "id": "PHP3478",
                "label": "GENTAMICIN",
                "type": "drug"
            },
            {
                "id": "PHP3486",
                "label": "AMIKACIN",
                "type": "drug"
            },
            {
                "id": "PHP3492",
                "label": "TOBRAMYCIN",
                "type": "drug"
            },
            {
                "id": "PHP3636",
                "label": "STREPTOMYCIN",
                "type": "drug"
            }
        ]
    }
}